Cite
HARVARD Citation
Lewin, J. et al. (2021). A phase 1b trial of selinexor, a first-in-class selective inhibitor of nuclear export (SINE), in combination with doxorubicin in patients with advanced soft tissue sarcomas (STS). European journal of cancer. pp. 360-367. [Online].